ClinicalTrials.gg
CompletedNCT05089851Updated Oct 28, 2021

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

An interventional study of Onabotulinumtoxin A and Facial Cleanser in Wrinkles, Photoaging and Fine Lines, sponsored by Revision Skincare. Completed at 3 sites in United States. Open to female participants aged 35 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Revision Skincare · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Jun 2021, 5 years 5 months ago, and no results have been posted to the registry.
  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2020, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
35 Years to 60 Years
Sex
Female
01

Study summary

This randomized, multi-center, double-blinded, placebo-controlled, split-face clinical trial was conducted to evaluate the procedure-pairing of OnabotulinumtoxinA with a peptide anti-aging serum to improve facial lines and wrinkles, as well as overall skin texture and radiance of the face after 12 weeks of twice-daily use in female subjects ages 35 - 60 as compared to placebo. A total of 29 subjects completed study participation.

Read the detailed description

This randomized, multi-center, double-blinded, placebo-controlled, split-face clinical trial was conducted to evaluate procedure pairing of a peptide anti-aging serum with Onabotulinumtoxin A in the treatment of periorbital facial wrinkles when used over the course of 12 weeks by women with moderate to severe crow's feet wrinkles and fine lines, and mild to moderate photoaging.

Efficacy and tolerability will be assessed through clinical grading at baseline, weeks 4, 8 and 12. Efficacy evaluation for wrinkles, fine lines, and skin appearance will be graded at rest and at maximum smile for each side. Investigator and subject tolerability, self-assessment questionnaire and VISIA photography will be completed at baseline, weeks 4, 8 and 12.

A total of 29 subjects completed study participation.

02

Conditions studied

  • Wrinkles
  • Photoaging
  • Fine Lines

Keywords

  • anti-aging
  • serum
  • onabotulinum toxin A
  • Botox
03

In context

Lead sponsor

Revision Skincare is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects must be between 35-60 years of age.
  2. Female subjects of must be willing to use a form of during the study.
  3. Subjects with Fitzpatrick I-VI photo skin type.
  4. Subjects must have moderate to severe crow's feet facial wrinkles (score 4-7 on 0-9 scale) using modified Griffith's 10-point scale.
  5. Subjects must have moderate to severe crow's feet fine lines (score 4-7 on 0-9 scale) using modified Griffith's 10-point scale.
  6. Subjects may have mild to moderate photo-aging (score 3-6 on 0-9 scale) secondary to physiologic aging, hormonal influences, and environmental stressors.
  7. Subjects must have no skin disease in the facial area being evaluated.
  8. Subjects must have no known medical conditions that, in the investigator's opinion, may interfere with study participation.
  9. Subjects must be willing to provide verbal understanding and written

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, breast feeding, or planning a pregnancy.
  2. Subjects with severe overall photo damage (score 7-9 on 0-9 scale) as determined by the Investigator.
  3. Subjects who have demonstrated a previous reaction to any of the ingredients of the study products or to the botulinum toxin.
  4. Subjects who are unwilling or unable to comply with the requirements of the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    Peptide Antiaging Serum

    Dosage Form: Serum composed of water, thickener, and bioactive ingredients including peptides and antioxidants. Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization. Study Duration: 12 weeks

    Procedure: Onabotulinumtoxin A · Combination Product: Facial Cleanser · Combination Product: Facial Moisturizer · Combination Product: Sunscreen

  • Placebo comparator
    Placebo Serum

    Dosage Form: Serum composed of water and thickener Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization. Study Duration: 12 weeks

    Procedure: Onabotulinumtoxin A · Combination Product: Facial Cleanser · Combination Product: Facial Moisturizer · Combination Product: Sunscreen

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Efficacy Grading by Griffith's Scale

    The primary efficacy endpoint will be the Investigator Clinical Grading using Modified Griffith's 10 point scale. A change in scores at Day 28, Day 56, and Day 84 (+/- 3 days) in comparison to baseline indicates an improvement for the indicated parameter. The efficacy parameters will be assessed at rest and at maximum smile and at specific areas on both the left and right sides of the subjects face using a modified Griffith's 10 point scale according to the following numerical definitions (half point scores may be used as necessary to more accurately describe skin conditions) 0 = None (best possible condition) 1 to 3 = Mild 4 to 6 = Moderate 7 to 9 = Severe (worst possible condition). The lower the score equates to the best possible outcome.

    Time frame: 12 weeks

  2. Tolerability Scores

    The primary tolerability endpoint will be Investigator Tolerability Assessment of erythema, edema, and dryness. A change in scores or lack of significant change at Day 28, Day 56, and Day 84 in comparison to baseline indicates tolerability / safety of the test material. Four point scale with a lower score indicating a better outcome. 0 = None 1. = Mild 2. = Moderate 3. = Severe

    Time frame: 12 weeks

  3. Incidence of Adverse Events

    The primary safety endpoint will be determined by the incidence and severity of adverse events in healthy subjects, including immediate post-procedure and through-out the length of the study.

    Time frame: 12 weeks

Secondary outcomes

  1. Self-Assessment Questionnaire

    The secondary efficacy endpoint will be the Self-Assessment Questionnaire. A change in response values at Day 28, Day 56, and Day 84 indicates and improvement compared to baseline response values. Subjects are asked to rate based on a scoring system of the following: from 5 (completely agree) to 1 (completely disagree). The best outcome is to Completely Agree with the statement / question being asked.

    Time frame: 12 weeks

  2. Secondary Tolerability Scores

    The secondary tolerability endpoint will be Subject Tolerability Assessment of burning, itching, and stinging. A change in scores or lack of significant change at Day 28, Day 56, Day 84, and Day 168 in comparison to baseline indicates tolerability / safety of the test material. Four point scale with a lower score indicating a better outcome. 0 = None 1. = Mild 2. = Moderate 3. = Severe

    Time frame: 12 weeks

07

Study locations

3 sites
  • Shino Bay Cosmetic Dermatology and Laser Institute
    Fort Lauderdale, Florida 33301, United States
  • Infinity Skin Care
    Coralville, Iowa 52241, United States
  • Juvly Aesthetics
    Columbus, Ohio 43215, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jun 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Oct 22, 2021
StartActual
Aug 23, 2020
Primary completionActual
Jun 3, 2021
CompletionActual
Jun 3, 2021
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05089851
Lead sponsor
Revision Skincare
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Aug 23, 2020
Primary completion
Jun 3, 2021
Completion
Jun 3, 2021
Last update
Oct 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion

Start the discussion